GO:1902260 negative regulation of delayed rectifier potassium channel activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902260 describes any process that stops, prevents, or reduces the frequency, rate, or extent of delayed rectifier potassium channel activity.
• Delayed rectifier potassium channels, including KCNQ1 (Kv7.1) and Kv2.1, are critical for action potential repolarization in excitable cells.
• Negative regulation of these channels can occur through direct protein-protein interactions, such as TMC4 acting on KCNQ1, or via phosphorylation by PKC isoforms.
• Dysregulation of delayed rectifier potassium channels is linked to long QT syndrome, cardiac arrhythmias, and cancer progression.
• Key research methods include patch-clamp electrophysiology, CRISPR knockout/knock-in models, and biochemical interaction assays.
• Understanding this process aids in identifying therapeutic targets for arrhythmias and cancers driven by potassium channel dysfunction.
Description
The Gene Ontology term GO:1902260, negative regulation of delayed rectifier potassium channel activity, defines any biological process that reduces the functional activity of delayed rectifier potassium channels. These channels are voltage-gated potassium channels that mediate the slow outward potassium current (IK) responsible for repolarizing the cardiac action potential and regulating excitability in neurons and other tissues. Their dysfunction is directly implicated in inherited cardiac arrhythmias, such as long QT syndrome type 1, where mutations in KCNQ1 alter IKs regulation and increase arrhythmic risk. Beyond the heart, delayed rectifier channels like Kv2.1 influence cancer cell proliferation and survival, making their negative regulation a potential therapeutic avenue. Researchers study this process to understand how signaling pathways, protein interactions, and pharmacological agents modulate channel function, with implications for drug development and disease modeling.
negative regulation of delayed rectifier potassium channel activity At A Glance
| GO ID | GO:1902260 |
|---|---|
| GO term | negative regulation of delayed rectifier potassium channel activity |
| Ontology | biological_process |
| Synonym | down regulation of delayed rectifier potassium channel activity, down-regulation of delayed rectifier potassium channel activity, downregulation of delayed rectifier potassium channel activity, inhibition of delayed rectifier potassium channel activity |
| Major function | Reduces the activity of delayed rectifier potassium channels, which are key for action potential repolarization and cellular excitability. |
| Related channels | KCNQ1 (Kv7.1), Kv2.1, KCNQ4, and other voltage-gated potassium channels. |
| Regulatory mechanisms | Protein-protein interactions, phosphorylation by PKC isoforms, neurotransmitter and magnesium modulation. |
| Disease relevance | Long QT syndrome, cardiac arrhythmias, cancer, and auditory disorders. |
What Is GO:1902260?
GO:1902260 encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of delayed rectifier potassium channel activity. This includes mechanisms such as direct channel inhibition by accessory proteins, phosphorylation-driven changes in gating, or modulation by neurotransmitters and ions. The term is a biological process and is distinct from positive regulation or general regulation of these channels.
Why Is negative regulation of delayed rectifier potassium channel activity Important in Cell Biology?
Negative regulation of delayed rectifier potassium channel activity is crucial because these channels control the duration of action potentials and the refractory period in excitable cells. Impaired regulation can lead to life-threatening arrhythmias, as seen in long QT syndrome where mutations in KCNQ1 affect IKs regulation and increase arrhythmic risk. In cancer, inhibition of Kv2.1 reduces malignant properties of triple-negative breast cancer cells, highlighting the therapeutic potential of targeting this process. Additionally, in the auditory pathway, KCNQ4 regulation is essential for hearing, and its dysfunction causes deafness. Thus, understanding the molecular players and pathways that negatively regulate delayed rectifier channels is fundamental for both basic physiology and clinical translation.
• Controls cardiac action potential repolarization; dysregulation causes long QT syndrome and arrhythmias.
• Modulates neuronal excitability and neurotransmitter release.
• Affects cancer cell proliferation and survival, with Kv2.1 inhibition reducing malignant properties.
• Regulates auditory function through KCNQ4 channels in the inner ear.
• Influences vascular tone via potassium channels in cerebral blood vessels.
• Provides targets for pharmacological intervention in cardiac and neurological disorders.
• Involves direct protein-protein interactions, such as TMC4 negatively regulating KCNQ1.
• Phosphorylation by PKC isoforms modulates channel activity and receptor desensitization.
• CRISPR-based models enable precise dissection of regulatory mechanisms.
• Bioinformatics and electrophysiology are key to identifying novel regulators.
What Happens During negative regulation of delayed rectifier potassium channel activity?
Initiation by Regulatory Proteins or Signals
In simple terms: A signal or protein binds to the channel and starts the process of shutting it down.
Negative regulation begins when specific proteins or signaling molecules interact with delayed rectifier potassium channels. For example, TMC4 acts as a negative regulator of KCNQ1 (Kv7.1) by direct interaction, reducing channel activity. Similarly, mutant α1B-adrenergic receptors can modulate KCNQ1/KCNE1 channels through PKC-isoform specific pathways. Neurotransmitters and magnesium also regulate the cardiac delayed rectifier K current, indicating that extracellular signals can initiate negative regulation.
Phosphorylation and Post-Translational Modifications
In simple terms: Chemical tags like phosphate groups are added to the channel, changing its behavior.
Phosphorylation by protein kinase C (PKC) isoforms is a key mechanism for negative regulation. PKC-isoform specific regulation of KCNQ1/KCNE1 channel activity by mutant α1B-adrenergic receptors leads to reduced channel function. This modification can alter channel gating, trafficking, or stability, ultimately decreasing the delayed rectifier current.
Direct Channel Inhibition and Gating Changes
In simple terms: The channel pore is blocked or its opening is made less likely.
Direct binding of inhibitory proteins or small molecules can block the channel pore or stabilize closed states. TMC4 negatively regulates KCNQ1 by likely affecting its gating or surface expression. In cancer cells, targeting Kv2.1 with inhibitors reduces channel activity and inhibits malignant properties. These events reduce the outward potassium current, prolonging action potentials.
Downstream Effects on Cellular Excitability
In simple terms: Less potassium flows out, so cells take longer to reset after firing.
Reduced delayed rectifier potassium channel activity leads to prolonged action potential duration and increased excitability. In the heart, this manifests as prolonged QT interval and increased risk of arrhythmias. In neurons, it can alter firing patterns and neurotransmitter release. In cancer cells, it can affect proliferation and survival.
Key Genes Involved in GO:1902260 negative regulation of delayed rectifier potassium channel activity
The following genes and proteins are central to the negative regulation of delayed rectifier potassium channel activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KCNQ1 | Forms the pore of the slow delayed rectifier potassium channel (IKs); mutations cause long QT syndrome type 1. | Target for negative regulation by TMC4 and PKC pathways. |
| KCNE1 | Auxiliary subunit that modulates KCNQ1 channel activity. | Its regulation affects IKs current and cardiac repolarization. |
| TMC4 | Transmembrane channel-like 4; acts as a negative regulator of KCNQ1 (Kv7.1). | Novel regulator; potential therapeutic target for arrhythmias. |
| Kv2.1 (KCNB1) | Voltage-gated potassium channel; its inhibition reduces cancer cell malignancy. | Target for negative regulation in cancer therapy. |
| KCNQ4 | Delayed rectifier potassium channel in auditory pathway. | Regulation is critical for hearing; mutations cause deafness. |
| PKC isoforms | Phosphorylate KCNQ1/KCNE1 channels, reducing activity. | Key signaling mediators of negative regulation. |
| α1B-adrenergic receptor | Mutant forms regulate KCNQ1/KCNE1 via PKC. | Links G-protein signaling to channel inhibition. |
| Magnesium | Modulates cardiac delayed rectifier K current. | Ion that can negatively regulate channel activity. |
| Neurotransmitters | Regulate cardiac delayed rectifier K current. | Physiological modulators of channel activity. |
| KCNH2 (hERG) | Delayed rectifier potassium channel; dysfunction causes arrhythmias. | Related channel; negative regulation may affect repolarization. |
| KCNQ1 S6 region | Mutations in this region affect IKs regulation and arrhythmic risk. | Hotspot for long QT syndrome type 1. |
| Kv7.1 | Alternative name for KCNQ1; target of TMC4. | Model for studying negative regulation. |
| Kv2.1 inhibitors | Small molecules that block Kv2.1 activity. | Potential anti-cancer agents. |
| PKC-α | Specific PKC isoform involved in channel regulation. | Isoform-specific effects on KCNQ1/KCNE1. |
| PKC-ε | Another PKC isoform modulating channel desensitization. | Contributes to negative regulation. |
| Cerebral blood vessel K+ channels | Regulate vascular tone. | Role in cerebral circulation. |
How Is negative regulation of delayed rectifier potassium channel activity Regulated?
The negative regulation of delayed rectifier potassium channel activity is itself controlled by various signaling pathways. PKC isoforms are activated by G-protein coupled receptors, such as mutant α1B-adrenergic receptors, leading to phosphorylation and inhibition of KCNQ1/KCNE1 channels. Neurotransmitters and magnesium can also modulate the cardiac delayed rectifier K current, indicating that extracellular signals fine-tune channel activity. Additionally, direct protein-protein interactions, like TMC4 binding to KCNQ1, provide a layer of regulation independent of phosphorylation. These regulatory mechanisms ensure appropriate action potential duration and cellular excitability.
negative regulation of delayed rectifier potassium channel activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KCNQ1 | Long QT syndrome type 1; arrhythmic risk | Knock-in mouse models with S6 mutations; hiPSC-derived cardiomyocytes |
| Kv2.1 (KCNB1) | Triple-negative breast cancer | MDA-MB-436 cell line with Kv2.1 knockout or overexpression |
| KCNQ4 | Auditory neuropathy; hearing loss | Kcnq4 knockout mice; cochlear hair cells |
| KCNH2 (hERG) | Long QT syndrome type 2; arrhythmias | Heterologous expression systems; CRISPR knock-in |
| TMC4 | Potential regulator of KCNQ1 in cardiac arrhythmia | TMC4 knockout and overexpression in cardiomyocytes |
Long QT Syndrome and Cardiac Arrhythmias
Mutations in KCNQ1, particularly in the S6 region, alter IKs regulation and increase the risk of arrhythmic events in long QT syndrome type 1. Dysfunction of delayed rectifier potassium channels, including hERG, is a well-established cause of inherited cardiac arrhythmias. Negative regulation of these channels can exacerbate repolarization abnormalities, leading to life-threatening ventricular tachyarrhythmias.
Cancer
In triple-negative breast cancer cells (MDA-MB-436), inhibition of the Kv2.1 channel reduces cancerous properties such as proliferation and migration. This suggests that negative regulation of delayed rectifier potassium channels, particularly Kv2.1, may have therapeutic potential in oncology.
Auditory Disorders
KCNQ4 is a delayed rectifier potassium channel essential for hearing. Its regulation in the auditory pathway is critical, and mutations cause progressive hearing loss. Negative regulation of KCNQ4 may contribute to auditory dysfunction, making it a target for research.
Cerebrovascular Disease
Potassium channels in cerebral blood vessels regulate vascular tone. Alterations in their activity, including negative regulation, can affect cerebral blood flow and contribute to stroke or vascular dementia.
From negative regulation of delayed rectifier potassium channel activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TMC4 negatively regulate KCNQ1 in vivo? | TMC4 knockout mouse; cardiac-specific overexpression |
| How do PKC isoforms modulate KCNQ1/KCNE1? | Point mutations in PKC phosphorylation sites; knock-in mice |
| Can Kv2.1 inhibition reduce tumor growth? | Kv2.1 knockout cancer cell lines; xenograft models |
| What is the role of KCNQ4 regulation in hearing? | Kcnq4 knock-in mice with human mutations |
| How do neurotransmitters affect delayed rectifier current? | Isolated cardiomyocytes; patch-clamp with neurotransmitter application |
| Does magnesium modulate IKs? | Overexpression of KCNQ1/KCNE1 in HEK293 cells; electrophysiology |
How to Study the negative regulation of delayed rectifier potassium channel activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Ion channel current and gating | Assessing negative regulation by TMC4 or PKC |
| CRISPR knockout | Loss of gene function | Determining if a gene is required for negative regulation |
| CRISPR knock-in | Introduction of specific mutations | Modeling long QT syndrome mutations in KCNQ1 |
| Co-immunoprecipitation | Protein-protein interactions | Detecting TMC4-KCNQ1 binding |
| Phospho-specific Western blot | Phosphorylation status of channels | Measuring PKC-mediated phosphorylation |
| RNA-seq | Transcriptional changes | Identifying compensatory changes after channel inhibition |
| Proteomics | Protein expression and modifications | Global analysis of regulatory networks |
| Live-cell imaging | Channel trafficking and localization | Visualizing KCNQ1 surface expression |
Patch-Clamp Electrophysiology
Patch-clamp recordings are the gold standard for measuring delayed rectifier potassium channel activity. They allow direct assessment of current amplitude, voltage dependence, and kinetics in response to negative regulators. This method can be applied to heterologous expression systems, cardiomyocytes, or cancer cells.
CRISPR-Cas9 Genome Editing
CRISPR knockout, knock-in, and point mutation models enable precise dissection of gene function in the context of channel regulation. For example, knocking out TMC4 can reveal its role as a negative regulator of KCNQ1. Point mutations in KCNQ1 S6 region can mimic long QT syndrome mutations.
Biochemical Interaction Assays
Co-immunoprecipitation, pull-down, and proximity ligation assays can identify protein-protein interactions between channels and their regulators, such as TMC4 and KCNQ1. These methods help map the molecular players involved in negative regulation.
Phosphorylation Analysis
Western blotting with phospho-specific antibodies and kinase assays can detect PKC-mediated phosphorylation of KCNQ1/KCNE1 channels. This is crucial for understanding how signaling pathways negatively regulate channel activity.
How CRISPR Can Be Used to Study GO:1902260 negative regulation of delayed rectifier potassium channel activity
Knockout
CRISPR knockout of candidate negative regulators, such as TMC4, can confirm their role in reducing delayed rectifier potassium channel activity. For example, TMC4 knockout cells show increased KCNQ1 current, validating TMC4 as a negative regulator. Knockout of Kv2.1 in cancer cells reduces malignant properties, demonstrating the functional importance of this channel.
Point Mutation
Introducing point mutations in channel genes, such as KCNQ1 S6 region, can mimic disease-associated variants and reveal how specific residues affect regulation and arrhythmic risk. Point mutations in PKC phosphorylation sites can prevent negative regulation by kinases.
Knock-in
Knock-in of mutant alleles, such as mutant α1B-adrenergic receptors, allows study of their effects on KCNQ1/KCNE1 channel activity in a physiological context. Knock-in mouse models carrying human KCNQ1 mutations are valuable for studying long QT syndrome.
Overexpression
Overexpression of negative regulators like TMC4 or PKC isoforms can suppress delayed rectifier potassium channel activity, providing a gain-of-function approach to study downstream effects. Overexpression of Kv2.1 in cancer cells may increase malignancy, while its inhibition reduces it.
How EDITGENE Supports negative regulation of delayed rectifier potassium channel activity Research
Researchers studying negative regulation of delayed rectifier potassium channel activity-related genes often need to determine whether a candidate gene is causally involved in modulating channel function, and to dissect the precise molecular mechanisms. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of delayed rectifier potassium channel activity research.
Frequently Asked Questions About negative regulation of delayed rectifier potassium channel activity
What is GO:1902260?
GO:1902260 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of delayed rectifier potassium channel activity.
What genes are involved in negative regulation of delayed rectifier potassium channel activity?
Key genes include KCNQ1, KCNE1, TMC4, Kv2.1, KCNQ4, and PKC isoforms, as well as adrenergic receptors.
How does TMC4 regulate KCNQ1?
TMC4 acts as a negative regulator of KCNQ1 (Kv7.1) by direct interaction, reducing its potassium channel activity.
What diseases are associated with delayed rectifier potassium channel dysfunction?
Long QT syndrome, cardiac arrhythmias, cancer, auditory disorders, and cerebrovascular diseases are linked to dysfunction of these channels.
What methods are used to study negative regulation of delayed rectifier potassium channels?
Patch-clamp electrophysiology, CRISPR knockout/knock-in, co-immunoprecipitation, phosphorylation assays, and RNA-seq are commonly used.
Can CRISPR be used to model long QT syndrome?
Yes, CRISPR knock-in of KCNQ1 mutations, such as those in the S6 region, can model long QT syndrome type 1 and study arrhythmic risk.
How does PKC regulate KCNQ1/KCNE1 channels?
PKC isoforms phosphorylate KCNQ1/KCNE1 channels, leading to reduced channel activity and altered receptor desensitization.
Is Kv2.1 a target for cancer therapy?
Inhibition of Kv2.1 reduces cancerous properties of triple-negative breast cancer cells, suggesting it as a potential therapeutic target.
What is the role of KCNQ4 in hearing?
KCNQ4 is a delayed rectifier potassium channel essential for auditory function; its regulation is critical for hearing, and mutations cause deafness.
How do neurotransmitters affect delayed rectifier potassium current?
Neurotransmitters can modulate the cardiac delayed rectifier K current, contributing to negative regulation of channel activity.
Conclusion
GO:1902260, negative regulation of delayed rectifier potassium channel activity, is a critical biological process that controls cellular excitability and cardiac repolarization. Dysregulation of this process is implicated in long QT syndrome, cancer, and auditory disorders, making it a key area of biomedical research. Advances in CRISPR genome editing and electrophysiology continue to uncover the molecular players, such as TMC4 and PKC isoforms, that mediate this negative regulation. Understanding these mechanisms offers promising avenues for therapeutic intervention.
References
- 1. Schwartz PJ et al.. 2021. Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region.. Eur Heart J 42(46):4743-4755 PMID: 34505893
- 2. Sanguinetti MC. 1999. Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia.. Ann N Y Acad Sci 868:406-13 PMID: 10414310
- 3. Hartzell HC et al.. 1993. Regulation of the cardiac delayed rectifier K current by neurotransmitters and magnesium.. Cardiovasc Drugs Ther 7 Suppl 3:547-54 PMID: 7902737
- 4. Aoyagi H et al.. 2026. Transmembrane channel-like 4 (TMC4) could act as a negative regulator of KCNQ1 (Kv7.1) potassium channel.. Biochim Biophys Acta Biomembr 1868(1):184460 PMID: 41046027
- 5. Renkhold L et al.. 2022. PKC-isoform specific regulation of receptor desensitization and KCNQ1/KCNE1 K(+) channel activity by mutant α(1B)-adrenergic receptors.. Cell Signal 91:110228 PMID: 34958868
- 6. Canella R et al.. 2025. Inhibition of cancerous properties of triple-negative MDA-MB-436 cells by targeting the K(+) voltage-dependent Kv2.1 channel.. J Physiol Biochem 81(4):1185-1198 PMID: 41184693
- 7. Chambard JM et al.. 2005. Regulation of the voltage-gated potassium channel KCNQ4 in the auditory pathway.. Pflugers Arch 450(1):34-44 PMID: 15660259
- 8. Kitazono T et al.. 1995. Role of potassium channels in cerebral blood vessels.. Stroke 26(9):1713-23 PMID: 7660420
